Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice

Cardiovascular Research

Volumn 96, Issue 3, 2012, Pages 422-432

  Velten, Markus ^a   Duerr, Georg D ^a   Pessies, Thilo ^a   Schild, Julia ^a   Lohner, Ralph ^a   Mersmann, Jan ^b   Dewald, Oliver ^a   Zacharowski, Kai ^b   Klaschik, Sven ^a   Hilbert, Tobias ^a   Hoeft, Andreas ^a   Baumgarten, Georg ^a   Meyer, Rainer ^c   Boehm, Olaf ^a   Knuefermann, Pascal ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Cardiac hypertrophy; Cytokine; Cytosine phosphate guanine oligodeoxynucleotide; Inflammation; Innate immunity; Transverse aortic constriction

Indexed keywords

1612 THIOATE; 1668 THIOATE; COLLAGEN; CPG OLIGODEOXYNUCLEOTIDE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATE BUFFERED SALINE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CARDITIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL SIZE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE INFARCTION; HEART VENTRICLE REMODELING; HEART WEIGHT; M MODE ECHOCARDIOGRAPHY; MACROPHAGE ACTIVATION; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRESSURE VOLUME CURVE; PRIORITY JOURNAL;

ANIMALS; CARDIAC CATHETERIZATION; CARDIOMEGALY; CARDIOTONIC AGENTS; CHEMOKINE CCL2; CHEMOKINE CCL4; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART FAILURE; INFLAMMATION MEDIATORS; LIGANDS; MACROPHAGE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MYOCARDITIS; MYOCARDIUM; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TOLL-LIKE RECEPTOR 9; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84869396139     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs280     Document Type: Article

References (46)

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562. (Pubitemid 26154241)
2. Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ Res 2009;105:1149-1158.
3. Weber KT, Jalil JE, Janicki JS, Pick R. Myocardial collagen remodeling in pressure overload hypertrophy. A case for interstitial heart disease. Am J Hypertens 1989;2:931-940. (Pubitemid 20046711)
4. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998;16:1031-1041. (Pubitemid 28367959)
5. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009;11:119-129.
6. Baumgarten G, Knuefermann P, Kalra D, Gao F, Taffet GE, Michael L et al. Load-dependent and-independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 2002;105:2192-2197. (Pubitemid 34517164)
7. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005;68:224-234. (Pubitemid 41428419)
8. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res 2011;89:744-753.
9. Dewald O, Frangogiannis NG, Zoerlein M, Duerr GD, Klemm C, Knuefermann P et al. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc Natl Acad Sci USA 2003;100:2700-2705. (Pubitemid 36297562)
10. Ren G, Dewald O, Frangogiannis NG. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy 2003;2:242-256.
11. Li T, Wang Y, Liu C, Hu Y, Wu M, Li J et al. MyD88-dependent nuclear factor-kB activation is involved in fibrinogen-induced hypertrophic response of cardiomyocytes. J Hypertens 2009;27:1084-1093.
12. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 2010;87:989-999.
13. Frantz S, Ertl G, Bauersachs J. Toll-like receptor signaling in the ischemic heart. Front Biosci 2008;13:5772-5779.
14. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 2011;8:292-300.
15. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999;104:271-280.
16. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA et al. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004; 109:784-789. (Pubitemid 38222900)
17. Stapel H, Kim SC, Osterkamp S, Knuefermann P, Hoeft A, Meyer R et al. Toll-like receptor 4 modulates myocardial ischaemia-reperfusion injury: role of matrix metallo-proteinases. Eur J Heart Fail 2006;8:665-672. (Pubitemid 44635319)
18. Rowland RT, Meng X, Cleveland JC Jr, Meldrum DR, Harken AH, Brown JM. LPS-induced delayed myocardial adaptation enhances acute preconditioning to optimize postischemic cardiac function. Am J Physiol 1997;272:H2708-H2715.
19. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP et al. Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci 2011;31:8456-8463.
20. Sparwasser T, Miethke T, Lipford G, Erdmann A, Hacker H, Heeg K et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-a-mediated shock. Eur J Immunol 1997;27:1671-1679. (Pubitemid 27302848)
21. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
22. Knuefermann P, Schwederski M, Velten M, Krings P, Ehrentraut H, Rudiger M et al. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of toll-like receptor 9. Cardiovasc Res 2008;78:26-35. (Pubitemid 351430962)
23. Liu YY, Cai WF, Yang HZ, Cui B, Chen ZR, Liu HZ et al. Bacillus Calmette-Guérin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment. J Immunol 2008;180:7349-7357.
24. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 1991; 88:8277-8281. (Pubitemid 21915339)
25. Duerr GD, Elhafi N, Bostani T, Ellinger J, Swieny L, Kolobara E et al. Comparison of myocardial remodeling between cryoinfarction and reperfused infarction in mice. J Biomed Biotechnol 2011;2011:961298.
26. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
27. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003;19:2448-2455. (Pubitemid 38016644)
28. Shioura KM, Geenen DL, Goldspink PH. Assessment of cardiac function with the pressure-volume conductance system following myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2007;293:H2870-H2877. (Pubitemid 350106510)
29. Renkl AC, Wussler J, Ahrens T, Thoma K, Kon S, Uede T et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005;106:946-955. (Pubitemid 41076439)
30. Rittling SR. Osteopontin in macrophage function. Expert Rev Mol Med 2011;13:e15.
31. 1. Mol Genet Metab 2000;71:418-435.
32. Klaschik S, Tross D, Shirota H, Klinman DM. Short-and long-term changes in gene expression mediated by the activation of TLR9. Mol Immunol 2010;47:1317-1324.
33. Nakamura A, Rokosh DG, Paccanaro M, Yee RR, Simpson PC, Grossman W et al. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol 2001;281:H1104-H1112.
34. Hoffman BD, Grashoff C, Schwartz MA. Dynamic molecular processes mediate cellular mechanotransduction. Nature 2011;475:316-323.
35. Ock S, Ahn J, Lee SH, Park H, Son JW, Oh JG et al. Receptor activator of nuclear factor-kB ligand is a novel inducer of myocardial inflammation. Cardiovasc Res 2012; 94:105-114.
36. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005;28:483-490. (Pubitemid 41195386)
37. Renault MA, Robbesyn F, Reant P, Douin V, Daret D, Allieres C et al. Osteopontin expression in cardiomyocytes induces dilated cardiomyopathy. Circ Heart Fail 2010; 3:431-439.
38. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Tolllike receptor signaling. Proc Natl Acad Sci USA 2004;101:15416-15421. (Pubitemid 39441556)
39. Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Bluml S, Grebien F et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010;207:2689-2701.
40. Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNAmediated Th1 response. J Immunol 2002;168:4711-4720. (Pubitemid 34441379)
41. Hu CM, Chen YH, Chiang MT, Chau LY. Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo. Circulation 2004;110:309-316.
42. Small EM, Thatcher JE, Sutherland LB, Kinoshita H, Gerard RD, Richardson JA et al. Myocardin-related transcription factor-A controls myofibroblast activation and fibro-sis in response to myocardial infarction. Circ Res 2010;107:294-304.
43. Ha T, Li Y, Gao X, McMullen JR, Shioi T, Izumo S et al. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkB activation in vivo. Free Radic Biol Med 2005; 39:1570-1580. (Pubitemid 41642588)
44. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2008;51:302-308. (Pubitemid 351159943)
45. Ehrentraut H, Weber C, Ehrentraut S, Schwederski M, Boehm O, Knuefermann P et al. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. Eur J Heart Fail 2011;13:602-610.
46. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC. Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res 2002; 30:e48.